Galecto, Inc. Common Stock (GLTO) is a publicly traded Healthcare sector company. As of May 21, 2026, GLTO trades at $28.69 with a market cap of $1.73B and a P/E ratio of 5.43. GLTO moved -0.21% today. Year to date, GLTO is +236.34%; over the trailing twelve months it is +606.65%. Its 52-week range spans $2.01 to $38.33. Analyst consensus is buy with an average price target of $43.67. Rallies surfaces GLTO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Damora Therapeutics to Trade Under DMRA, Secures $535M Cash, Targets Mid-2026 IND: Galecto, now rebranded as Damora Therapeutics, will trade under the symbol DMRA on Nasdaq beginning March 10, 2026 after its Damora acquisition and $285 million private investment. It holds $535 million in cash as of February 28, 2026 and will file IND for DMR-001 by mid-2026 with proof-of-concept data expected mid-2027.
| Metric | Value |
|---|---|
| Price | $28.69 |
| Market Cap | $1.73B |
| P/E Ratio | 5.43 |
| EPS | $5.28 |
| Dividend Yield | 0.00% |
| 52-Week High | $38.33 |
| 52-Week Low | $2.01 |
| Volume | 231.69K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.16M |
| Net Income | $-235.02M |
| Gross Margin | 0.00% |
5 analysts cover GLTO: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $43.67.